Cosibelimab (UNLOXCYT; cosibelimab-ipdl) is an anti-PD-L1 antibody developed by Checkpoint Therapeutics for the treatment of advanced cancers, including metastatic or locally advanced cutaneous squamo...

Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell...

The FDA has approved Unloxcyt (cosibelimab-ipdl) to treat advanced cutaneous squamous cell carcinoma.

More than 71% of patients treated with Unloxcyt achieved disease control

The U.S. Food and Drug Administration has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.

More than 71% of patients treated with Unloxcyt achieved disease control

New Delhi: Sun Pharmaceutical Industries Limited has announced that UNLOXCYT (cosibelimab-ipdl) is now available in the United States for prescription by healthcare professionals for the treatment...

The U.S. Food and Drug Administration has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.

Sun Pharma on Saturday reported a 15% increase in its third quarter sales to Rs 15,469 crore, while net profit was up 16% year-on-year to Rs 3,368 crore, driven by growth across its branded businesses in India, emerging markets and global innovative medicines. “Our innovative product offering has expanded further with the launch of Unloxcyt in the US and the introduction of Ilumya in India. Together, these new initiatives bring differentiated therapies and meaningful innovation closer to the patients,” said Kirti Ganorkar, Managing Director, Sun Pharma. The company’s Board has declared an interim dividend of Rs.

Sun Pharmaceutical Industries will present significant long-term follow-up results of UNLOXCYT at the ASCO 2026 Annual Meeting. The data showcases efficacy in treating skin cancer.

Sun Pharmaceutical Industries has introduced UNLOXCYT™, a new option for treating advanced cutaneous squamous cell carcinoma in the U.S., offering significant benefits for patients.

The FDA has updated the label for UNLOXCYT™, an innovative treatment for advanced squamous cell carcinoma, showcasing improved outcomes based on long-term data.

Sun Pharmaceutical Industries has successfully acquired Checkpoint Therapeutics, gaining access to UNLOXCYT™, an FDA-approved treatment for skin cancer, marking a significant step forward in oncology.

Sun Pharma's acquisition of Checkpoint Therapeutics will enable better access to UNLOXCYT™, the first FDA-approved treatment for advanced skin cancer.

Sun Pharma, India’s largest drugmaker, is acquiring Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and targeted oncology company, for $355 million (over Rs 3,000 crore).The acquisition will bolster the company’s specialty portfolio.Checkpoint is a commercial-stage company that develops novel treatments for patients with solid tumor cancers, and the acquisition includes UNLOXCYT, an FDA-approved treatment for advanced skin cancer, says a company statement.Dilip Shanghvi, CMD of Sun Pharma, said, “Combining UNLOXCYT, an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma’s global presence means patients may soon have access to an important, new treatment option.

Revenue reached $63.3M and cash stood at $79.4M after a year that also added a 2.5% UNLOXCYT royalty stream. Fortress cut annual net loss sharply.